Human African Trypanosomiasis (HAT) Platform

Founded: 2005, Kinshasa, Democratic Republic of the Congo

The HAT platform builds and strengthens treatment methodologies and clinical trial capacity in sleeping sickness-endemic countries, so that new treatments for this fatal disease can be rapidly and effectively evaluated, registered, and made available to patients. After the success of the Nifurtimox-Eflornithine Combination Therapy (NECT), included in the WHO List of Essential Medicines for the treatment of stage 2 HAT, the primary goals of the HAT Platform are to develop appropriate clinical trial methodologies for sleeping sickness, overcome system challenges related to administrative and regulatory requirements, strengthen clinical trial capacity (human resources, infrastructure, equipment), and share information and strengthen ties among endemic countries.

 

tawaba_hat‘The training in good clinical practice and the site initiation of the clinical study, help me on a daily basis to improve the way we take care of all patients.’

Tawaba Say Watson, Head Nurse
Bagata, Kwilu province, DRC

HAT Platform Map

The Platform is active in:

  • Treatments & access
  • Clinical trials
  • Capacity strengthening
  • Communications

Read HAT Platform Publications

2015 Highlights

  • Recruitment of patients to the fexinidaole Phase II/III study was completed (394 patients).
  • Participated in the 33rd International Scientific Council of Research and Control of Trypanosomiasis in Ndjamena, Chad, with 53 attendees.

In the Media

[17 September, 2014]
Radio Okapi
“Dr Augustin Kadima Ebeja : ‘La RDC est le pays le plus endémique
de la maladie du sommeil'”
Dr Augustin Kadima Ebeja en ‘Invité du Jour’ sur Radio Okapi (interview audio)
Click here to read the article

[17 September, 2014]
Radio Okapi
“Les moyens manquent”
Interview de Dr Augustin Kadima Ebeja
Click here to read the article